Profile
Benjamin John Nathan Griffiths was associated with Abcellute Ltd.
where he held the position of Chief Scientific Officer from 2001 to 2012.
He is the founder of Abcellute Ltd.
which was founded in 2001.
Former positions of Benjamin John Nathan Griffiths
Companies | Position | End |
---|---|---|
Abcellute Ltd.
Abcellute Ltd. Miscellaneous Commercial ServicesCommercial Services Abcellute was founded in September 2001 as a spinout from the school of biosciences, Cardiff University. Abcellute's core technology is proprietary media Sure Tran -that enables the extended use of fresh cells with out the need for cryopreservation. The company's vision is to achieve global adoption of its SureTran cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximize the utilization of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine. | Founder | 2012-11-19 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Abcellute Ltd.
Abcellute Ltd. Miscellaneous Commercial ServicesCommercial Services Abcellute was founded in September 2001 as a spinout from the school of biosciences, Cardiff University. Abcellute's core technology is proprietary media Sure Tran -that enables the extended use of fresh cells with out the need for cryopreservation. The company's vision is to achieve global adoption of its SureTran cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximize the utilization of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine. | Commercial Services |
- Stock Market
- Insiders
- Benjamin John Nathan Griffiths